echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > J Allergy Clin Immunol: Nimolidin monoantigen can quickly and continuously improve skin inflammation and itching symptoms in patients with adjuevative dermatitis.

    J Allergy Clin Immunol: Nimolidin monoantigen can quickly and continuously improve skin inflammation and itching symptoms in patients with adjuevative dermatitis.

    • Last Update: 2020-09-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Nimoli beads are resistant to il-31 recepposes alpha sub-units in targeted adpogenic dermatitis (AD).
    this study was designed to evaluate new drug strategies for Nemorydin monoantigen in AD patients.
    We conducted a 24-week randomized, double-blind, multi-center study in which adults with moderate to severe AD, severe itching, and inadequate local treatment control were injected every 4 weeks with subdermal injections of Nemoricin monotherapy (10, 30 and 90 mg) and placebo, local corticosteroids.
    the eczema area and severity index (EASI), the Itch Peak (PP) numerical score sheet (NRS), and the Researcher Global Assessment (IGA).
    standard security assessment was carried out.
    results showed that Nimoli beads improved EASI, IGA and/or NRS-itch scores, with a dose of 30 mg being the most effective.
    Compared to placebos, Nimolidin (30mg) reduced the EASI score at week 24 (-68.8% vs -52.1%, P .016);
    had a significant improvement as early as week 4 (P s .028), and at week 16, the IGA 0/1 rate of 30 mg nemodin monothecera was significantly higher than that of placebo (33.1) 3% vs 12.3%, P - .008), but not in week 24 because of increased placebo/local corticosteroid effect (36.8% vs 21.1%, P - .06).
    in Week 16 (-68.6% vs .34.3%, P.lt; .0001) and weeks 24 (-67.3% vs -35.8%, P .lt; .0001), 30mg of nemorydin monothecetics improved relative to placebo PP-NRS scores, with significant differences to week 1 (P .lt; .001).
    in weeks 16 (P s .001) and week 24 (P s .01), the 30mg nemory beads were more resistant to NRS than the placebo (down by 4 points).
    nemoli beads are safe and well tolerated.
    most common adverse events are nasopharyngitis and upper respiratory tract infections.
    summary, the results of the study show that Nimoli beads can quickly and continuously improve skin inflammation and itching symptoms in AD patients, with maximum efficacy observed at 30 mg doses.
    safety of the Nemoli beads is acceptable.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.